Precigen, Inc. Common Stock
Here’s whether Precigen, Inc. Common Stock (PGEN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); RSI 58 — healthy momentum range; strong 1-year return of +190.5%. Concerns: 50-day MA is falling (-2.94% over 10 days); 3-month momentum negative (-9.8%); declining volume on rally — weak conviction (0.65x 30d avg). Currently 27.2% off its 52-week high. Score: +2/7.
PGEN is in a confirmed uptrend, trading above both its 50-day ($3.90) and 200-day ($3.63) moving averages. An RSI of 57.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +190.5% compares to +35.1% for SPY (beat the market by 155.4%). The current 27.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.